Skip to content

Our Solutions
- Radiomic Precision Metrics
  AI-Enabled precision imaging and segmentation
  - Radiomic Discovery Services
    Translating radiomics into action
- Radiomic Informed Workflows
Request a Demo
Who we serve
Our Technology
- Radiomics Software
Request a Demo
HealthMyne® Achieves
HITRUST CSF® Certification to Further Mitigate Risk in Third-Party Privacy, Security, and Compliance

Read More »
Resources
- Thought Leadership
Request a Demo
Webinar

Explore the Depths of Radiomic Data in Clinical Trials

Join us for this interactive panel to explore the depths of radiomic data in clinical trials.

Watch now »
About
- Our Story
  - Our Partners
  - Leadership Team
- News & Events
  - Careers
Request a Demo
HealthMyne Partners with Flywheel to Provide End-to-End Radiomic Data Management and Analysis

Read More »
Contact Us
Search

Drug Discovery & Development

December 15, 2021 | Coverage

By Rose Higgins

Rose Higgins, CEO of HealthMyne shares her prediction for Pharma in 2022. Read how radiomics adoption continues to gain steam in drug development.

Click here to read full article

Follow us:

© 2022 HealthMyne. All rights reserved.

Compliance
Privacy Policy
Cookie Policy
Terms of Use
Sitemap

Our website uses cookies to provide our users with the best possible experience. Please refer to our updated privacy policy for more information.

Got It

Search

×